Abstract
In addition to the basic functions, opsonization and cytolysis, associated with the complement system there are some physiological activities elicited by complement peptides which contribute significantly to antimicrobial defence in infectious diseases and to the physiological and pathological consequences of immune complex formation, in short to the benefit and burden of inflammation. These effects depend on the cleavage of low-molecular-weight activation peptides from C4, C3 and C5: the anaphylatoxic peptides or anaphylatoxins C4a, C3a and C5a. The known primary structures1 are given in Table 11.1. Generated from the N-termini of the a-chains of C4, C3 or C5 via activation of the classical or alternative pathways of complement, they interact with specific receptors on a number of cell types of the phagocytic system, mainly granulocytes and monocytes/macrophages. In addition, endothelial cells, possibly some T-cell subsets and, in some species, platelets express anaphylatoxin-receptors. Although the C5a receptor is often expressed with the C3a/C4a receptor, they are distinct species. The ligand-receptor interaction triggers G-protein coupled signal transduction pathways and results in a number of cellular responses2-15, the most significant of which are documented in Table 11.2. Some of these biological effects are in general use as highly sensitive and specific in vitro detection systems for anaphylatoxins, e.g. smooth muscle contraction, enzyme release, stimulation of the respiratory burst, histamine release, ATP release,
Keywords
- SystemiC Lupus Erythematosus
- Complement Activation
- Adult Respiratory Distress Syndrome
- Septic Primate
- Terminal Complement Complex
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Download to read the full chapter text
Chapter PDF
Similar content being viewed by others
References
Bitter-Suermann, D. (1987). The anaphylatoxins. In Rother, K. and Till, G. (eds.) The Complement System, pp. 367–395. (Heidelberg: Springer Verlag)
Johnson, A. R., Hugh, T. E. and Miiller-Eberhard, H. J. (1975). Release of histamine from mast cells by the complement peptides C3a and C5a. Immunology, 28, 1067–1087
Grossklaus, C, Damerau, B., Lemgo, E. and Vogt, W. (1976). Induction of platelet aggregation by the complement-derived peptides C3a and C5a. Naunyn-Schmiedeberg’s Arch. Pharmacol., 295, 71–76
Meuer, S., Ecker, U., Hadding, U. and Bitter-Suermann, D.(1981). Platelet serotonin-release by C3a and C5a. Two independent pathways of activation. J. Immunol., 126, 1506–1509
Zanker, B., Rasokat, H., Hadding, U. and Bitter-Suermann, D. (1982). C3a induced activation and stimulus specific desensitization of guinea pig platelets. Agents Actions (Suppl), 11, 147–157
Hartung, H. P., Bitter-Suermann, D. and Hadding, U. (1983). Induction of thromboxane release from macrophages by anaphylatoxic peptide C3a of complement and synthetic hexapeptide C3a. J. Immunol., 130, 72–77
Dias da Silva, W. and Lepow, I. (1967). Complement as a mediator of inflammation. II. Biological properties of anaphylatoxin prepared with purified components of human complement. J. Exp. Med., 125, 921–946
Björk, J., Hugh, T. E. and Smedegard, G. (1985). Microvascular effects of anaphylatoxins C3a and C5a. J. Immunol., 134, 1115–1119
Fernandez, H. N., Henson, P. M, Otani, A. and Hugli, T. E. (1978). Chemotactic response to human C3a and C5a anaphylatoxins. I. Evaluation of C3a and C5a leukotaxis in vitro under simulated in vivo conditions. J. Immunol., 120, 102–108
Goldstein, I. M. and Weissmann, G. (1974). Generation of C5-derived lysosomal enzyme-releasing activity (C5a) by lysates of leucocyte lysosomes. J. Immunol., 113, 1583–1588
Goldstein, I. M., Ross, D., Kaplan, H. B. and Weissmann, G. (1975). Complement and immunoglobulins stimulate superoxide production by human leucocytes independently of phagocytosis. J. Clin. Invest., 56, 1155–1163
Haeffner-Cavaillon, N., Cavaillon, J. M., Laude, M. and Kazatchkine, M. D. (1987). C3a (desarg) induces production and release of interleukin 1 by cultured human monocytes. J. Immunol. 139, 794–799
Goodmann, M. G., Chenoweth, D. E. and Weigle, W. O. (1982). Induction of interleukin 1 secretion and enhancement of humoral immunity by binding of human C5a to macrophage surface C5a receptors. J. Exp. Med., 1156, 912–917
Bischoff, S. C, De Week, A. L. and Dahinden, C. A. (1990). Interleukin 3 granulocyte/macrophage-colony-stimulating factor render human basophils responsive to low concentrations of complement component C3a. Proc. Natl. Acad. Sci. USA, 87, 6813–6817
Kurimoto, Y., De Week, A. L. and Dahinden, A. (1989). Interleukin 3 dependent mediator release in basophils triggered by C5a. J. Exp. Med., 170, 467–479
Klos, A., Ihrig, V., Messner, M., Grabbe, J. and Bitter-Suermann, D. (1988). Detection of native human complement components C3 and C5 and their primary activation peptides C3a and C5a (anaphylatoxic peptides) by ELISA’s with monoclonal antibodies. J. Immunol. Meth., 241, 241–252
Burger, R., Zilow, G., Bader, A., Friedlein, A. and Naser, W. (1988). The C terminus of the anaphylatoxin C3a generated upon complement activation represents a neoantigenic determinant with diagnostic potential. J. Immunol., 141, 553–558
Hugli T. E. and Chenoweth D. E. (1980). Biologically active peptides of complement: Techniques and significance of C3a and C5a measurements. In Immunoassays: Clinical Laboratory Technique for the 1980s pp. 443–460. (New York: A.R. Liss Inc.
Nilsson, B., Svensson, K. E., Inganas, M., and Nilsson, U. R. (1988). A simplified assay for the detection of C3a in human plasma employing a monoclonal antibody raised against denatured C3. J. Immunol. Meth., 107, 281–287
Takeda, J., Kinoshita, T., Takata, Y., Kozono, H., Tanaka, E., Hong, K., and Inoue, K., (1987). Rapid and simple measurement of human C5a-des-Arg level in plasma or serum using monoclonal antibodies. J. Immunol. Meth., 101, 265–270
Oppermann, M., Schulze, M. and Gotze, O. (1991). A sensitive enzyme immunoassay for the quantitation of human C5a/C5a (desArg) anaphylatoxin using a monoclonal antibody with specificity for a neoepitope. Complement Inflamm., 8, 13–24
Meuer, S., Zanker, B., Hadding, U. and Bitter-Suermann, D. (1982). Low zone desensitization: a stimulus-specific control mechanism of cell-response. Investigations on anaphylatoxin-induced platelet-secretion. J. Exp. Med., 155, 698–710
Craddock, P. R., Fehr, J., Dalmasso, A. P., Brigham, K. L. and Jacob, H. S. (1977). Hemodialysis leucopenia: pulmonary vascular leucostasis resulting from complement activation by dialyzer cellophane membranes. J. Clin. Invest., 59, 879–888
Gerardy-Schahn, R., Ambrosius, D., Casaretto, M., Grotzinger, J., Saunders, D., Wollmer, A., Brandenburg, D. and Bitter-Suermann, D. (1988). Design and biological activity of a new generation of synthetic C3a analogues by combination of peptidic and non-peptidic elements. Biochem. J., 255, 209–216
Ember, J. A., Johansen, N. L. and Hugli, T. E. (1991). Designing synthetic superagonists of C3a anaphylatoxin. Biochemistry, 30, 3603–3612
Mandecki, W., Mollison, K. W., Boiling, T. J., Powell, B. S., Carter, G. W. and Fox, J. L. (1985). Chemical synthesis of a gene encoding the human complement fragment C5a and its expression in Escherichia coli. Proc. Natl. Acad. Sci. USA, 82, 3542–3547
Mollison, K. W., Mandecki, L.W.L., Zuiderweg, E. R. P., Fayer, L., Fey, T. A., Krause, R. A., Conway, R. G., Miller, L., Edalji, R. P., Shallcross, M. A., Lane, B., Fox, J. L., Greer, J. and Carter, G. W. (1989). Identification of receptor-binding residues in the inflammatory complement protein C5a by site-directed mutagenesis. Proc. Natl. Acad. Sci. USA, 86, 292–296
Köhl, J., Casaretto, M., Gier, M., Karwath, G., Gietz, C, Bautsch, W., Saunders, D. and Bitter-Suermann, D. (1990). Reevaluation of the C3a active site using short synthetic C3a analogues. Eur. J. Immunol., 20, 1463–1468
Hugli, T. E. (1986). Biochemistry and biology of anaphylatoxins. Complement, 3, 111–127
Köhl, J., Kola, A., Bautsch, W. and Bitter-Suermann, D. (1991). Comparative analysis of synthetic anaphylatoxic peptides in ATP-release and ileum contraction assay. Complement Inflamm., 8, 175
Fukuoka, Y. and Hugli, T. E. (1988). Demonstration of a specific C3a receptor on guinea pig platelets. J. Immunol., 140, 3496–3501
Gerardy-Schahn, R., Ambrosius, D., Saunders, D., Casaretto, M., Mittler, C, Karwath, G., Gbrgen, S. and Bitter-Suermann, D. (1989). Characterization of C3a receptor-proteins on guinea pig platelets and human polymorphonuclear leukocytes. Eur. J. Immunol., 19, 1095–1102
Grotzinger, J., Engels, M., Jacoby, E. and Wollmer, A. (1991). A model for the C5a receptor and for its interaction with the ligand. Protein Eng., 4, 767–771
Bautsch, W., Stuhmer, T., Emde, M., Kretzschmar, T., Köhl, J. and Bitter-Suermann, D. (1991). A recombinant hybrid anaphylatoxin with dual C3a/C5a activity. Complement Inflamm., 8, 127–128
Jacob, H. S., Craddock, P. R., Hammerschmidt, D. E. and Moldow, C. R. (1980). Complement-induced granulocyte aggregation. N. Engl. J. Med., 302, 789–794
Rollins, T. E. and Springer, M. S. (1985). Identification of the polymorphonuclear leukocyte C5a receptor. J. Biol. Chem., 260, 7157–7160
Kretzschmar, T., Kahl, K., Rech, K., Bautsch, W., Köhl, J. and Bitter-Suermann, D. (1991). Characterization of the C5a receptor on guinea pig platelets. Immunobiology, 183, 418–432
Gerard, N. P. and Gerard, C. (1991). The chemotactic receptor for human C5a and anaphylatoxin. Nature, 349, 614–617
Boulay, F., Mery, L., Tardif, M., Brouchon, L. and Vignais, P. (1991). Expression cloning of a receptor for C5a anaphylatoxin on differential HL-60 cells. Biochemistry, 30, 2993–2999
Boulay, F., Tardiff, M., Brouchon, L. and Vignais, P. (1990). Synthesis and use of a novel N-formyl peptide derivative to isolate a human N-formyl peptide receptor cDNA. Biochem. Biophys. Res. Commun., 168, 1103–1109
Dixon, R. A., Kobilka, B. K., Strader, D. J., Benovic, J. L., Dohlman, H. G., Frielle, T., Bolanowski, M. A., Bennett, C. D., Rands, E. and Diehl, R. E. (1986). Cloning of the gene and cDNA for mammalian beta-adrenergic receptor and homology with rhodopsin. Nature, 321, 75–79
Gerard, N. P. and Gerard, C. (1990). Construction and expression of a novel recombinant anaphylatoxin, C5a-N19, as a probe for the human C5a receptor. Biochemistry, 29, 9274–9281
Morgan, E. L. (1986). Modulation of the immune response by anaphylatoxins. Complement, 3, 128–136
Morgan, E. L., Thoman, M. L., Hobbs, M. V., Weigle, W. O. and Hugh, T. E. (1985). Human C3a-mediated suppression of the immune responses. II. Suppression of human in vitro polyclonal antibody responses occurs through the generation of nonspecific OKT8+ suppressor T cells. Clin. Immunol. Immunopathol., 37, 114–123
Morgan, E. L. (1987). The role of prostaglandins in C3a-mediated suppression of human in vitro polyclonal antibody responses. Clin. Immunol. Immunopathol., 44, 1–11
Morgan, E. L., Weigle, W. O., Erickson, B. W., Fok, K. F. and Hugh, T. E. (1983). Suppression of humoral immune responses by synthetic C3a peptides. J. Immunol., 131, 2258–2261
Morgan, E. L., Weigle, W. O. and Hugh, T. E. (1984). Anaphylatoxin-mediated regulation of human and murine immune responses. Fed. Proc, 43, 2543–2547
Morgan, E. L., Thoman, M. L., Weigle, W. O. and Hugh, T. E. (1983). Anaphylatoxin-mediated regulation of the immune response. II. C5a-mediated enhancement of human humoral and T cell-mediated immune responses. J. Immunol., 130, 1257–1261
Scholz, W., McClurg, M. R., Cardenas, G. J., Smith, M., Noonan, D. J., Hugli, T. E. and Morgan, E. L. (1990). C5a-mediated release of interleukin 6 by human monocytes. Clin. Immunol. Immunopathol., 57, 297–307
Rinaldo, J. E. and Rogers, R. M. (1982). Adult respiratory distress syndrome-changing concepts of lung injury and repair. N. Engl. J. Med., 306, 900–909
Simon, R. H. and Ward, P. A. (1988). Adult Respiratory Distress Syndrome Inflammation: Basic Principles and Clinical Correlates, pp. 815–826. (New York: Raven Press, Ltd.)
Herndon, D. N. and Traber, D. L. (1990). Pulmonary failure and acute respiratory distress syndrome. Multiple organ failure. In: Deitch, E. A. (ed.), Pathophysiology and Basic Concepts of Therapy, pp. 192–214. (New York: Thieme)
Hoffman, T., Bottger, E. C, Baum, H. P., Dennebaum, R., Hadding, U. and Bitter-Suermann, D. (1986). Evaluation of low dose anaphylatoxin peptides in the pathogenesis of the adult respiratory distress syndrome (ARDS). Monitoring of early C5a effects in a guinea pig in vivo model after i.v. application. Eur. J. Clin. Invest., 16, 500–508
Hoffmann, T., Bottger, E. C, Baum, H. P., Messner, M., Hadding, U. and Bitter-Suermann, D. (1988). In vivo effects of C3a on neutrophils and its contribution to inflammatory lung processes in a guinea pig model. Clin. Exp. Immunol., 71, 486–492
Lo, S. K., van Seventer, G. A., Levin, S. M. and Wright, S. D. (1989). Two leukocyte receptors (CD 11 a/CD 18 and CD1 lb/CD 18) mediate transient adhesion to endothelium by binding to different ligands. J. Immunol., 143, 3325–3329
Lo, S. K., Detmers, P. A., Levin, S. M. and Wright, S. D. (1989). Transient adhesion of neutrophils to endothelium. J. Exp. Med., 169, 1779–1793
Tonnesen, M. G. (1989). Neutrophil-endothelial cell interaction mechanism of neutrophil adherence to vascular endothelium. J. Invest. Dermatol., 93, 53S–58S
Tonnesen, M. G., Anderson, D. C, Springer, T. A., Knedler, A., Avdi, N. and Henson, P. M. (1989). Adherence of neutrophils to cultured human microvascular endothelial cells. Stimulation by chemotactic peptides and lipid mediators and dependence upon the mac-1, lfa-1, p. 150,95 glycoprotein family. J. Clin. Invest., 83, 637–646
Yancey, K. B., Lawley, T. J., Dersookian, M. and Harvath, L. (1989). Analysis of the interaction of human C5a and C5a desarg with human monocytes and neutrophils: flow cytometric and chemotaxis studies. J. Invest. Dermatol., 92, 184–189
Goodman, M. C, Chenoweth, D. E. and Weigle, W. O. (1982). Induction of interleukin-1 secretion and enhancement of humoral immunity by binding of human C5a to macrophage surface C5a receptors. J. Exp. Med., 156, 6652
Burger, R., Bader, A., Kirschtink, M., Rother, U., Schrod, L., Worner, I., Zilow, G. (1987). Functional analysis and quantification of the complement C3 derived anaphylatoxin C3a with a monoclonal antibody. Clin. Exp. Immunol, 68, 703–711
Stimler, N. P., Hugli, T. E. and Bloor, C. M. (1980). Pulmonary injury induced by C3a and C5a anaphylatoxins. Am. J. Pathol., 100, 327–328
Huey, R., Bloor, C. M., Kawahara, M. S. and Hugli, T. E. (1983). Potentiation of the anaphylatoxins in vivo using an inhibitor of serum carboxypeptidase N (SCPN). I. Lethality and pathologic effects on pulmonary tissue. Am. J. Pathol., 112, 48–60
Hangen, D. H., Segall, G. M., Harney, E. W., Stevens, J. H., McDougall, I. R. and Raffin, T. A. (1990). Kinetics of leukocyte sequestration in the lungs of acutely septic primates. A study using 111 lN-labelled autologuos leukocytes. J. Surg. Res., 48, 196–203
Hangen, D. H., Stevens, J. H., Satoh, P. S., Hall, E. W., O’Hanley, P. T. and Raffin, T. A. (1989). Complement levels in septic primates treated with anti-C5a antibodies. J. Surg. Res., 46, 195–199
Stevens, J. H., O’Hanley, P., Shapiro, J. M., Mihm, F. G., Satoh, P. S., Collins, J. A. and Raffin, T. A. (1986). Effects of anti-C5a antibodies in the adult respiratory distress syndrome in septic primates. J. Clin. Invest., 77, 1812–1818
Worthen, G. S., Haslett, C, Rees, J., Irving, C. G., Gumbay, R. S., Henson, J. E. and Henson, P. M. (1987). Neutrophil-mediated pulmonary vascular injury: synergistic effect of trace amounts of lipopolysaccharide and neutrophil stimuli on vascular permeability and neutrophil sequestration in the lung. Am. Rev. Respir. Dis., 136, 19–28
Neumann, M. and Kownatzki, E. (1989). The effect of adherence on the generation of reactive oxygen species by human neutrophilic granulocytes. Agents Actions, 26, 183–185
Craddock, P. R. (1984). Complement, granulocytes and shock lung. Am. J. Emerg. Med., 2, 78–81
Till, G. O. and Ward, P. A. (1985). Oxygen radicals in complement and neutrophil mediated acute lung injury. J. Free Radical Biol. Med., 1, 163–168
Braude, S., Krausz, T., Apperley, J., Goldman, J. M. and Royston, D. (1985). Adult respiratory distress syndrome after allogenic bone-marrow transplantation: evidence for a neutrophil independent mechanism. Lancet, 1, 1239–1242
Laufe, M. D., Simon, H., Flint, A. and Keller, J. B. (1986). Adult respiratory distress syndrome in neutropenic patients. Am. J. Med., 80, 1022–1026
Maunder, R. J., Hackman, R. C, Riff, E., Albert, R. K. and Springmeyer, S. C. (1986). Occurrence of the adult respiratory distress syndrome in neutropenic patients. Am. Rev. Respir. Dis., 133, 313–316
Ognibene F. P. Martin S. E. Parker M. M. Schlesinger T. Roach P. Burch C. et al. 1986. Adult respiratory distress syndrome in patients with severe neutropenia. N. Engl. J. Med. 315 547–55
Fowler, A. A., Walchak, S., Giclas, P. C, Henson, P. H. and Hyers, T. M. (1982). Characterization of antiproteinase activity in the adult respiratory distress syndrome. Chest, 81, 50S–51S
Lee, C. T., Fein, A. M., Lippman, M., Holtzman, H., Kimbel, P. and Wienbaum, G. (1981). Elastolytic activity in pulmonary lavage fluid from patients with the adult respiratory distress syndrome. N. Engl. J. Med., 304, 192–196
McGuire, W. W., Spragg, R. G., Cohen, A. M. and Cochrane, C. G. (1982). Studies on the pathogenesis of the adult respiratory distress syndrome. J. Clin. Invest., 69, 543–553
Robbins, C. A., Russ, W. D., Rasmussen, J. K. and Clayton, M. M. (1987). Activation of the complement system in the adult respiratory distress syndrome. Am. Rev. Respir. Dis., 135, 651–658
Strunk, R. C, Eidlen, D. M. and Mason, R. J. (1988). Pulmonary alveolar type II epithelial cells synthesize and secrete proteins of the classical and alternative complement pathways. J. Clin. Invest., 81, 1419–1426
Moser, R., Schleiffenbaum, B., Groscurth, P. and Fehr, J. (1989). Interleukin 1 and tumor necrosis factor stimulate human vascular endothelial cells to promote transendothelial neutrophil passage. J. Clin. Invest., 83, 444–455
Schleiffenbaum, B. and Fehr, J. (1990). The tumor necrosis factor receptor and human neutrophil function. J. Clin. Invest., 86, 184–195
Porteu, F. and Nathan, C. (1990). Shedding of tumor necrosis factor receptors by activated human neutrophils. J. Exp. Med., 172, 599–607
Grisham, M. B., Evers, J. and Janssen, H. F. (1988). Endotoxemia and neutrophil activation in vivo. Am. J. Physiol., 254, H1017–H1022
Beutler, B., Milsark, I. W. and Cerami, A. C. (1985). Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science, 229, 869–871
Ohlsson, K., Bjork, P., Bergenfeldt, M., Hageman, R. and Thompson. R. C. (1990). Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature, 348, 550–553
Wakabayashi, G., Gelfand, J. A., Durke, J. K., Thompson, R. C. and Dinarello, C. A. (1991). A specific receptor antagonist for interleukin-1 prevents Escherichia coli-induced shock in rabbits. FASEB J., 5, 338–343
Smedegard, G., Lianxian, C. and Hugli, T. E. (1989). Endotoxin-induced shock in the rat: A role for C5a. Am. J. Pathol, 135, 489–497
Bengtson, A. and Heideman, M. (1988). Anaphylatoxin formation in sepsis. Arch. Surg., 123, 645–649
Davis, J. M, Meyer, J. D., Barie, P. S., Yurt, R. W., Duhaney, R., Dineen, P. and Shires, G. T. (1990). Elevated production of neutrophil leukotriene B4 precedes pulmonary failure in critically ill surgical patients. Surg. Gynecol. Obstet., 170, 495–500
Hallgren, R., Samuelsson, T. and Modig, J. (1987). Complement activation and increased alveolar-capillary permeability after major surgery and in adult respiratory distress syndrome. Crit. Care Med., 15, 189–193
Heidemann, M. and Hugli, T. E. (1984). Anaphylatoxin generation in multisystem organ failure. J. Trauma, 24, 1038–1043
Heidemann, M., Norder-Hanssen, B., Bengston, A. and Mollnes, T. E. (1988). Terminal complement complexes and anaphylatoxins in septic and ischemic patients. Arch. Surg., 123, 188–192
Lamy, M., Deby-Dupont, G., Pincemail, J., Braun, M., Dochateau, J., Deby, C., van Erck, J., Bodson, L., Damas, P. and Franchimont, P. (1985). Biochemical pathways of active lung injury. Bull. Eur. Physiopathol. Respir., 21, 221–229
Langlois, P. F., Gawryl, M. S., Zeller, J. and Lint, T. (1989). Accentuated complement activation in patient plasma during the adult respiratory distress syndrome: a potential mechanism for pulmonary inflammation. Heart Lung, 18, 71–84
Tennenberg, S. D., Jacobs, M. P. and Solomkin, J. S. (1987). Complement-mediated neutrophil activation in sepsis-and trauma-related adult respiratory distress syndrome. Clarification with radioaerosol lung scans. Arch. Surg., 122, 26–32
Hack, C. E., Nuijens, J. H., Felt-Bersma, R. J. F., Schreuder, W. O., Eerenberg-Belmer, A. J. M., Paardekooper, J., Bronsveld, W. and Thijs, L. G. (1989). Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with fatal outcome in sepsis. Am. J. Med., 86, 20–26
Kellermann, W., Frentzel-Beyme, R., Welte, M. and Jochum, M. (1989). Phospholipase a in acute lung injury after trauma and sepsis: its relation to the inflammatory mediators PMN-elastase, C3a and neopterin. Klin. Wochenschr., 67, 190–195
Solomkin, J. S., Cotta, L. A., Satoh, P. S., Hurst, J. M. and Nelson, R. D. (1985). Complement activation and clearance in acute illness and injury: evidence for c5a as a cell-directed mediator of the adult respiratory distress syndrome in man. Surgery, 97, 668–678
Weigelt, J. A., Chenoweth, D. E., Borman, K. R. and Norcross, J. F. (1988). Complement and the severity of pulmonary failure. J. Trauma, 28, 1013–1019
Zilow, G., Sturm, J. A., Rother, U. and Kirschfink, M. (1990). Complement activation and the prognostic value of C3a in patients at risk of adult respiratory distress syndrome. Clin. Exp. Immunol., 79, 151–157
Langlois, P. F. and Gawryl, M. S. (1988). Accentuated formation of the terminal C5b-9 complement complex in patient plasma precedes development of the adult respiratory distress syndrome. Am. Rev. Respir. Dis., 138, 368–375
Hack, C. E., DeGroot, E. R., Felt-Bersma, R. J., Nuijens, J. H., Strack Van Schijndel, R. J., Eerenberg-Belmer, A. J., Thijs, L. G. and Aarden, L. A. (1989). Increased plasma levels of interleukin 6 in sepsis. Blood, 74, 1704–1710
Chenoweth, D. E. (1987). The properties of human C5a anaphylatoxin. The significance of C5a formation during hemodialysis. Contrib. Nephrol., 59, 51–71
Chenoweth, D. E. (1986). Anaphylatoxin formation in extracorporal circuits. Complement, 3, 152–165
Bingel, M., Arndt, W., Schulze, M., Floege, J., Shaldon, S., Koch, K. M. and Goetze, O. (1989). Comparative studies of C5a plasma levels with different hemodialysis membranes using an enzyme-linked immunosorbent assay. Nephron, 51, 320–324
Deppisch, R., Schmitt, V., Bommer, J., Hansch, G. M., Ritz, E. and Rauterberg, E. W. (1990). Fluid phase generation of terminal complement complex as a novel index of bioincompatibility. Kidney Int., 37, 669–706
Schaefer, R. M., Rauterberg, E. W., Deppisch, R. and Vienken, J. (1990). Assembly of SC5b-9 complement complex: A new index of blood-membrane interaction. Miner. Electrolyte Metab., 16, 73–76
Chenoweth, D. E. and Henderson, L. W. (1987). Complement activation during hemodialysis: Laboratory evaluation of hemodialyzers. Artif. Organs, 11, 155–162
Falkenhagen, D., Bosch, T., Brown, G. S., Schmidt, B., Holtz, M., Baurmeister, U., Gurland, H. and Klinkmann, H. (1987). A clinical study on different cellulosic dialysis membranes. Nephrol. Dial. Transplant., 2, 537–545
Lucchi, L., Bonucchi, D., Acerbi, M. A., Cappelli, G., Spattini, A., Innocenti, M., Castellani, A. and Lusvarghi, E. (1989). Improved biocompatibility by modified cellulosic membranes: the case of hemophan. Artif. Organs, 13, 417–421
Cheung A. K. 1989. Adsorption of unactivated complement proteins by hemodialysis membranes. Am. J. Kidney Dis. 14 472–47
Cheung, A. K., Parker, J. F., Wilcox, L. A. and Janatova, J. (1990). Activation of complement by hemodialysis membranes: Polyacrylonitrile bind more C3a than Cuprophan. Kidney Int., 37, 1055–1059
Horl, E. I., Wanner, C, Frischmuth, N., Gosele, A. and Masry, S. G. (1990). Plasma levels of main granulocyte components during hemodialysis. Comparison of new and reused dialyzers. Am. J. Nephrol., 10, 53–57
Cavarocci, N. C, Schaff, H. V., Orszulak, T. A., Homburger, H. A., Schnell, W. A. Jr and Pluth, J. R. (1985). Evidence for complement activation by protamine-heparin interaction after cardiopulmonary bypass. Surgery, 89, 525–531
Shastri, K. A., Phillips, M. J., Raza, S., Logue, G. and Rustagi, P. K. (1988). Effects of RBCs on the activation of human complement by heparin-protamine complexes. Blood, 71, 36–40
Tan, F., Jackman, K., Skidgel, R. A., Zsigmond, E. K. and Erdos, E. G. (1989). Protamine inhibits plasma carboxypeptidase N, the inactivator of anaphylatoxins and kinins. Anaesthesiology, 70, 267–275
Click, R. L., Homburger, H. A. and Bove, A. A. (1989). Complement activation from protamine sulfate administration after coronary angiography. Cathet. Cardiovasc. Diagn., 16, 221–225
Lewis, S. L., Van Epps, D. E. and Chenoweth, D. E. (1987). Leukocyte C5a receptor modulation during hemodialysis. Kidney Int., 31, 112–120
Lewis, S. L. and Van Epps, D. E. (1987). Neutrophil and monocyte alternations in chronic dialysis patients. Am. J. Kidney Dis., 9, 381–395
Stahl, G. L., Amsterdam, E. A., Symons, J. D. and Longhurst, J. C. (1990). Role of thromboxane A2 in the cardiovascular response to intracoronary C5a. Circ. Res., 66, 1103–1111
Del Balzo, U., Sakuma, I. and Levi, R. (1990). Cardiac dysfunction caused by recombinant human C5a anaphylatoxin: mediation by histamine adenosine and cyclooxygenase arachidonate metabolites. J. Pharmacol. Exp. Ther., 253, 171–179
Ito, B. R., Roth, D. M. and Engler, R. L. (1990). Thromboxane A2 and peptidoleukotrienes contribute to the myocardial ischemia and contractile dysfunction in response to intracoronary infusion of complement C5a in pigs. Circ. Res., 66, 596–607
Del Balzo, U. H., Levi, R. and Polley, M. J. (1985). Cardiac dysfunction caused by purified human C3a anaphylatoxin. Proc. Natl. Acad. Sci. USA, 82, 886–890
Yasudam, M., Kawarabayashi, T., Akioka, K., Teragaki, M., Oku, H. and Kanayama, Y. (1989). The complement system in the acute phase of myocardial infarction. Jpn. Circ. J., 53, 1017–1022
Christophers, E. and Henseler, T. (1989). Patient subgroups and the inflammatory pattern in psoriasis. Acta Derm. Venereol. Suppl. Stockh., 151, 88–92
Takematsu H. Ohkohchi K. and Tagami H. 1986. Demonstration of anaphylatoxin C3a C4a and c5a in the scales of psoriasis and inflammatory pustular dermatoses. Br. J. Dermatol. 114 1–
Takematsu, H., Terui, T., Ohkohchi, K., Tagami, H., Suzuki, R. and Kuhmagi, K. (1986). Presence of chemotactic peptides other than C5a anaphylatoxin in scales of psoriasis and sterile pustular dermatoses. Acta Derm. Venereol. Suppl. Stockh., 66, 93–97
Takematsu, H., Terui, T. and Tagami, H. (1986). Demonstration of leukotriene B4 in the scale extracts of psoriasis and inflammatory pustular dermatoses. Correlation with leukocyte chemotactic activity and C5a anaphylatoxin. Acta Derm. Venereol. Suppl. Stockh., 66, 6–10
Schroder J. M. and Christophers E. 1986. Identification of C5a desarg and a neutrophil activating peptide ANAP in psoriatic scales. J. Invest. Dermatol. 87 53–5
Asbakk, K., Bergh, K. and Iversen, O. J. (1990). The psoriasis associated antigen, pso p27, participates in the formation of complement activating immune complexes in psoriatic scale. Acta Pathol. Microbiol. Immunol. Scand., 98, 143–149
Kapp, A., Wokalek, H. and Schopf, E. (1985). Involvement of complement in psoriasis and atopic dermatitis measurement of C3a and C5a, C3, C4 and CI inactivator. Arch. Dermatol. Res., 277, 359–361
Ohkochi, K., Takematsu, H. and Tagami, H. (1985). Increased anaphylatoxins (C3a and C4a) in psoriatic sera. Br. J. Dermatol., 113, 189–196
Weissmann, G. and Korchak, H. (1984). Rheumatoid arthritis. The role of neutrophil activation. Inflammation, 8, S3–S14
Moxley, G. and Rudy, S. (1987). Elevated plasma C3 anaphylatoxin levels in rheumatoid arthritis patients. Arthritis Rheum., 30, 1097–1104
Moxley, G. and Rudy, S. (1985). Elevated plasma C3 anaphylatoxin levels in synovial fluids from patients with rheumatoid arthritis. Arthritis Rheum., 28, 1089–1095
Haslett, C, Jose, P. J., Giclas, P. C, William, T. J. and Henson, P. M. (1989). Cessation of neutrophil influx in C5a-induced acute experimental arthritis is associated with loss of chemoattractant activity from the joint space. J. Immunol., 142, 3510–3517
Elmgreen, J. and Hansen, T. M. (1985). Subnormal sensitivity of neutrophils to complement split product C5a in rheumatoid arthritis: relation to complement catabolism and disease extent. Ann. Rheum. Dis., 44, 514–518
Hermann, E., Vogt, P., Hagemann, W., Dunky, A. and Muller, W. (1988). Synovial level of interleukin-1 and C3a in chronic polyarthritis, psoriatic arthritis and activated arthritis. Z. Rheumatol., 47, 20–50
Belmont, H. M., Hopkins, P., Edelson, H. S., Kaplan, H. B., Ludewig, R., Weissmann, G. and Abramson, S. (1986). Complement activation during systemic lupus erythematosus. C3a and C5a anaphylatoxins circulate during exacerbations of disease. Arthritis Rheum., 29, 1085–1089
Hopkins, P., Belmont, H. M., Buyon, J., Phillips, M., Weissmann, G. and Abramson, S. B. (1988). Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis. Arthritis Rheum. 31, 632–641
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Köhl, J., Bitter-Suermann, D. (1993). Anaphylatoxins. In: Whaley, K., Loos, M., Weiler, J.M. (eds) Complement in Health and Disease. Immunology and Medicine, vol 20. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-2214-6_11
Download citation
DOI: https://doi.org/10.1007/978-94-011-2214-6_11
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-4981-8
Online ISBN: 978-94-011-2214-6
eBook Packages: Springer Book Archive